Express Pharma
MAY 29, 2023
Hefei Tianhui Biotechnology (HTIT) has recently submitted a marketing authorisation application (MAA) in China for the world’s first oral insulin for type 2 diabetes (T2D). The number of diagnosed prevalent cases of type 2 diabetes in China is estimated to grow at a CAGR of 2.21 million in 2028, as per GlobalData.
Express Pharma
MAY 24, 2024
Innovent Biologics has unveiled Phase III (DREAMS-2) results for mazdutide, indicating superiority over dulaglutide in glycaemic control for type 2 diabetes (T2D) patients in China. per cent from 58.460,424 in 2023 to 63,342,654 in 2028. Dual agonism at GLP-1R and GCGR could potentially enhance efficacy beyond monotherapies.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 12, 2024
In a press release issued ahead of an investor meeting today, the company also said it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. … Moderna plans to cut its annual spending on research and development by 23%, or $1.1 The stock was trading 3.5%
European Pharmaceutical Review
JUNE 5, 2024
billion in 2028. million deaths from diabetes” worldwide. A report by the Business Research Company predicts that the small molecule injectable drugs market will value $355.14 As such, the compound annual growth rate (CAGR) is expected to be 12.8 percent up to this period. million deaths from cardiovascular diseases, 9.3
Express Pharma
MAY 30, 2024
million in 2023 to 9 million in 2028. In the APAC region, several factors contribute to the increasing prevalence of neurological disorders, including ageing populations, lifestyle changes, and the rising incidence of risk factors such as hypertension and diabetes.” per cent from 7.45 These include Eisai Co.
European Pharmaceutical Review
AUGUST 21, 2023
Its diabetes treatment Mounjaro led this outcome. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. billion to revenue in Q2 2023. billion in Q2 2023. With the company’s monoclonal antibody drug candidate PRA023 predicted to reach $2.1
Express Pharma
AUGUST 22, 2023
Lilly’s strong market capitalisation growth over Q2 was attributed to its diabetes drug Mounjaro, a synthetic peptide that reported $980 million in global sales, according to GlobalData’s Pharmaceutical Intelligence Center Drugs Database. per cent increase in market capitalisation.” billion by 2029, according to GlobalData’s Drugs Database.
Expert insights. Personalized for you.
94 
Let's personalize your content